目的 探讨槟榔十三味丸联合阿戈美拉汀治疗抑郁症的临床疗效。方法 选取2017年10月—2018年10月在中南大学湘雅二医院精神卫生中心治疗的抑郁症患者62例，根据用药的差别分为对照组（31例）和治疗组（31例）。对照组晚上口服阿戈美拉汀片，25 mg/次，1次/d，2周后若疗效欠佳可增至50 mg/d；治疗组在对照组基础上口服槟榔十三味丸，13粒/次，2次/d。两组患者均治疗6周。观察两组患者临床疗效，同时比较治疗前后两组患者蒙哥马利抑郁评定量表（MADRS）、匹兹堡睡眠质量指数（PSQI）表、生活质量综合评定量表（GQOLI-74）、世界卫生组织生存质量测定量表简表（WHOQOL-BREF）评分及血清白细胞介素-12（IL-12）、IL-6、同型半胱氨酸（Hcy）、5-羟吲哚乙酸（5-HIAA）和3-甲基-4-羟-苯乙二醇（MHPG）水平。结果 治疗后，对照组临床有效率为80.65%，显著低于治疗组的96.77%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者MADRS和PSQI评分显著降低（P<0.05），GQOLI-74和WHOQOL-BREF评分显著升高（P<0.05），且治疗组患者上述评分明显好于对照组患者（P<0.05）。治疗后，两组患者血清IL-12、IL-6、Hcy水平明显降低（P<0.05），5-HIAA、MHPG水平明显升高（P<0.05），且治疗组血清学指标明显好于对照组（P<0.05）。结论 槟榔十三味丸联合阿戈美拉汀可显著改善抑郁状态，有利于改善患者睡眠及生活质量，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Binglang Shisanwei Pills combined with agomelatine in treatment of depression. Methods Patients (62 cases) with depression in Mental Health Center of the Second Xiangya Hospital of Central South University from October 2017 to October 2018 were divided into control (31 cases) and treatment (31 cases) groups based on different treatments. Patients in the control group were po administered with Agomelatine Tablets at night, 25 mg/time, once daily, the dose was increased to 50 mg/d according the effect after 2 weeks. Patients in the treatment group were po administered with Binglang Shisanwei Pills on the basis of the control group, 13 pills/time, twice daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the MADRS, PSQI, GQOLI-74, and WHOQOL-BREF scores, serum IL-12, IL-6, Hcy, 5-HIAA, and MHPG levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.65%, which was significantly lower than 96.77% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the MADRS and PSQI scores in two groups were significantly decreased (P<0.05), but GQOLI-74 and WHOQOL-BREF scores in two groups were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum IL-12, IL-6, and Hcy levels in two groups were significantly decreased (P<0.05), but 5-HIAA and MHPG were significantly increased (P<0.05), and the serological indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Binglang Shisanwei Pills combined with agomelatine in treatment of depression can significantly improve the depressive status, the sleep and quality of life, which has a certain clinical application value.